-
Safety
-
Noxafil (posaconazole) Oral Suspension
Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) -- May 2008
| The detailed view includes drug products with safety labeling changes to the BOXED WARNING, CONTRAINDICATIONS, WARNINGS, PRECAUTIONS, ADVERSE REACTIONS, or PATIENT PACKAGE INSERT/MEDICATION GUIDE sections. Deletions or editorial revisions made to these sections are not included in this summary. |
| Sections Modified | Summary of Changes to Contraindications and Warnings |
|
CONTRAINDICATIONS PRECAUTIONS
PATIENT PACKAGE INSERT
|
CONTRAINDICATIONS ...Co-administration of Noxafil (posaconazole) with sirolimus is contraindicated ... |
Label approved 05/20/2008 is not available on Drugs@FDA
-
-

